Treatment exit options for non-infectious uveitis registry: participant characteristics at 3 years.
David Julian FinkJennifer DellCarsten HeinzMaximilian W M WintergerstTobias HöllerMoritz BergerMatthias SchmidKarl Thomas BodenUwe PleyerHerbert ReitsamerChristoph M E DeuterTibor K LohmannRobert P Fingernull nullPublished in: The British journal of ophthalmology (2024)
Less than half of participants required DMARD treatment at baseline, with csDMARDs used more frequently than bDMARDs. The presence of severe visual impairment was low, mostly affecting patients with panuveitis. These findings are in line with comparable monocentric cross-sectional studies of tertiary uveitis centres in Germany and will allow us to generate generalisable evidence in TOFU.